 Your new post is loading...
|
Scooped by
HAS-veille
|
|
Scooped by
HAS-veille
|
|
Scooped by
HAS-veille
|
Clinical severity of COVID-19 in patients admitted to hospital during the omicron wave in South Africa: a retrospective observational study
|
Scooped by
HAS-veille
|
We explored the risk factors associated with SARS-CoV-2 reinfections in Italy between August 2021 and March 2022. Regardless of the prevalent virus variant, being unvaccinated was the most relevant risk factor for reinfection. The risk of reinfection increased almost 18-fold following emergence of the Omicron variant compared with Delta. A severe first SARS-CoV-2 infection and age over 60 years were significant risk factors for severe reinfection.
|
Scooped by
HAS-veille
|
CDC recommends Pfizer COVID boosters for kids ages 5 to 11
|
Scooped by
HAS-veille
|
This cohort study investigates factors associated with anti–SARS-CoV-2 antibody levels.
|
Scooped by
HAS-veille
|
The Joint Committee on Vaccination and Immunisation (JCVI) has provided interim advice to government regarding coronavirus (COVID-19) booster doses this autumn.
|
Scooped by
HAS-veille
|
Patients identified by our models as potentially having long COVID can be interpreted as patients warranting care at a specialty clinic for long COVID, which is an essential proxy for long COVID diagnosis as its definition continues to evolve. We also achieve the urgent goal of identifying potential long COVID in patients for clinical trials. As more data sources are identified, our models can be retrained and tuned based on the needs of individual studies.
|
Scooped by
HAS-veille
|
Co-infections with different variants of SARS-CoV-2 are a key precursor to recombination events that are likely to drive SARS-CoV-2 evolution. Rapid identification of such co-infections is required to determine their frequency in the community, particularly in populations at-risk of severe COVID-19, which have already been identified as incubators for punctuated evolutionary events. However, limited data and tools are currently available to detect and characterise the SARS-CoV-2 co-infections associated with recognised variants of concern. Here we describe co-infection with the SARS-CoV-2 variants of concern Omicron and Delta in two epidemiologically unrelated adult patients with chronic kidney disease requiring maintenance haemodialysis. Both variants were co-circulating in the community at the time of detection. Genomic surveillance based on amplicon- and probe-based sequencing using short- and long-read technologies identified and quantified subpopulations of Delta and Omicron viruses in respiratory samples. These findings highlight the importance of integrated genomic surveillance in vulnerable populations and provide diagnostic pathways to recognise SARS-CoV-2 co-infection using genomic data. Here, using genomic approaches, Rockett et al. identify Omicron and Delta SARS-CoV-2 co-infections in two adults, highlighting the usefulness of genomic surveillance for the timely recognition of co-infections in situations when different variants of the virus are circulating in the community.
|
Scooped by
HAS-veille
|
Neutralization of Deltacron and BA.3 SARS-CoV-2 Variants A small study assessed the neutralization of pseudoviruses composed of the recombinant deltacron and omicron BA.3 variants. BA.3 did no
|
Scooped by
HAS-veille
|
SARS-CoV-2 is not unique in its ability to cause post-acute sequelae; certain acute infections have long been associated with an unexplained chronic disability in a minority of patients. These post-acute infection syndromes (PAISs) represent a substantial healthcare burden, but there is a lack of understanding of the underlying mechanisms, representing a significant blind spot in the field of medicine. The relatively similar symptom profiles of individual PAISs, irrespective of the infectious agent, as well as the overlap of clinical features with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), suggest the potential involvement of a common etiopathogenesis. In this Review, we summarize what is known about unexplained PAISs, provide context for post-acute sequelae of SARS-CoV-2 infection (PASC), and delineate the need for basic biomedical research into the underlying mechanisms behind this group of enigmatic chronic illnesses. Certain acute infections (including SARS-CoV-2) are associated with an unexplained chronic disability in a minority of patients; this Review summarizes what is known about these understudied and complex illnesses.
|
Scooped by
HAS-veille
|
|
Scooped by
HAS-veille
|
Scientists are trying to understand the cause of neurological effects and whether symptoms will be long-lasting
|
|
Scooped by
HAS-veille
|
Joint Committee on Vaccination and Immunisation (JCVI) interim statement on the COVID-19 vaccination programme for autumn 2022
|
Scooped by
HAS-veille
|
Omicron Infection in Canada With the emergence of the omicron variant of SARS-CoV-2 in November 2021, these investigators found how rapidly it had spread across Canada among both vaccinated an
|
Scooped by
HAS-veille
|
Background Changing patterns of vaccine breakthrough can clarify vaccine effectiveness. Aim To compare breakthrough infections during a SARS-CoV-2 Delta wave vs unvaccinated inpatients, and an earlier Alpha wave. Methods In an observational multicentre cohort study in Israel, hospitalised COVID-19 patients were divided into three cohorts: breakthrough infections in Comirnaty-vaccinated patients (VD; Jun–Aug 2021) and unvaccinated cases during the Delta wave (ND) and breakthrough infections during an earlier Alpha wave (VA; Jan–Apr 2021). Primary outcome was death or ventilation. Results We included 343 VD, 162 ND and 172 VA patients. VD were more likely older (OR: 1.06; 95% CI: 1.05–1.08), men (OR: 1.6; 95% CI: 1.0–2.5) and immunosuppressed (OR: 2.5; 95% CI: 1.1–5.5) vs ND. Median time between second vaccine dose and admission was 179 days (IQR: 166–187) in VD vs 41 days (IQR: 28–57.5) in VA. VD patients were less likely to be men (OR: 0.6; 95% CI: 0.4–0.9), immunosuppressed (OR: 0.3; 95% CI: 0.2–0.5) or have congestive heart failure (OR: 0.6; 95% CI: 0.3–0.9) vs VA. The outcome was similar between all cohorts and affected by age and immunosuppression and not by vaccination, variant or time from vaccination. Conclusions Vaccination was protective during the Delta variant wave, as suggested by older age and greater immunosuppression in vaccinated breakthrough vs unvaccinated inpatients. Nevertheless, compared with an earlier post-vaccination period, breakthrough infections 6 months post-vaccination occurred in healthier patients. Thus, waning immunity increased vulnerability during the Delta wave, which suggests boosters as a countermeasure.
|
Scooped by
HAS-veille
|
For the period of predominance of SARS-CoV-2 Omicron variant in Slovenia, February to March 2022, we estimated mRNA vaccine effectiveness (VE) against severe acute respiratory infection (SARI) COVID-19 using surveillance data. In the most vulnerable age group comprising individuals aged 65 years and more, VE against SARI COVID-19 was 95% (95% CI: 95–96%) for those vaccinated with three doses, in comparison to 82% (95% CI: 79–84%) for those vaccinated with two doses. Such levels of protection were maintained for at least 6 months.
|
Scooped by
HAS-veille
|
We propose a probabilistic model to quantify the cost-benefit of mass Vaccination Scenarios (VSs) against COVID-19. Through this approach, we conduct …
|
Scooped by
HAS-veille
|
This study examines outcomes of multisystem inflammatory syndrome in children during the Alpha, Delta, and Omicron variant waves of the COVID-19 pandemic in Israel.
|
Scooped by
HAS-veille
|
|
Scooped by
HAS-veille
|
|
Scooped by
HAS-veille
|
|
Scooped by
HAS-veille
|
|
Scooped by
HAS-veille
|
|
Scooped by
HAS-veille
|
BACKGROUND AND OBJECTIVES. Limited post-authorization safety data for BNT-162b2 COVID-19 vaccination among children ages 5–11 years are available, particularly for the adverse event myocarditis, which has been detected in adolescents and young adults. We describe adverse events observed during the first 4 months of the US COVID-19 vaccination program in this age group.METHODS. We analyzed data from 3 US safety monitoring systems: v-safe, a voluntary smartphone-based system that monitors reactions and health effects; the Vaccine Adverse Events Reporting System (VAERS), the national spontaneous reporting system co-managed by CDC and FDA; and the Vaccine Safety Datalink (VSD), an active surveillance system that monitors electronic health records for prespecified events, including myocarditis.RESULTS. Among 48,795 children ages 5–11 years enrolled in v-safe, most reported reactions were mild-to-moderate, most frequently reported the day after vaccination, and were more common after dose 2. VAERS received 7,578 adverse event reports; 97% were non-serious. On review of 194 serious VAERS reports, 15 myocarditis cases were verified; 8 occurred in males after dose 2 (reporting rate 2.2 per million doses). In VSD, no safety signals were detected in weekly sequential monitoring after administration of 726,820 doses.CONCLUSIONS. Safety findings for BNT-162b2 vaccine from 3 US monitoring systems in children ages 5–11 years show that most reported adverse events were mild and no safety signals were observed in active surveillance. VAERS reporting rates of myocarditis after dose 2 in this age group were substantially lower than those observed among adolescents ages 12–15 years.
|